©2024 Stanford Medicine
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
Not Recruiting
Trial ID: NCT01598558
Purpose
Rituximab is an antibody targeted against the CD20 antigen found primarily on B-cells.
Therefore, an imaging agent targeting CD20 expression may provide a more accurate evaluation
of extent of disease and response to therapy than the current standard of care, F-18 FDG
PET/CT.
The main purpose of the study is to investigate a new PET/CT imaging probe for detection and
follow up of lymphoma. Following are the 3 aims of the study: a) Phase I testing in lymphoma
patients of Cu-64 labelled Rituxan for defining normal tracer biodistribution, stability,
pharmacokinetics and radiation dosimetry; b) comparison of Cu-64 Rituxan and F-18 FDG PET/CT
in lymphoma patients; c) evaluation of changes in uptake of Cu-64 Rituxan in response to
rituximab-based treatment in CD20-positive B-cell NHL
Official Title
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Eligibility
Inclusion Criteria:
- Patients must have a diagnosis of CD20-positive B-cell NHL and a staging 18F FDG
PET/CT prior to the 64Cu-DOTA-Rituximab PET/CT
- Patients must understand and voluntarily sign an Informed Consent form after the
contents have been fully explained to them
- Patients must be scheduled for rituximab-based therapy
- Patients must be older than 18-year-old
Exclusion Criteria:
- Patients who cannot complete a PET/CT scan
- Pregnant women
- Patients participating in other research protocols will be excluded from this study
Intervention(s):
drug: Cu-64 Rituximab
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
ccto-office@stanford.edu
650-498-7061